TRAMOMTANA (Multidisciplinary treatment of morbid obesity: Medication, behavioral therapy, nutritional support, and physical activity). From question to reality in an investigator-initiated clinical trial (II) | Endocrinología y Nutrición (English Edition)

Article information

Abstract

The implementation of an intensive, multidisciplinary weight loss program in patients with morbid obesity is reported. This program is based on behavioral changes, lifestyle intervention, medication, and group therapy sessions. Our objective is to show that the results achieved with this two-year weight loss program will be at least similar to those achieved with bariatric surgery in patients with morbid obesity. We also intend to show that this multidisciplinary treatment induces an improvement in the comorbidity rate associated with lower costs for our national health system.

Keywords:

Weight loss program

Health education

Research methodology

Morbid obesity

Clinical trial

Interdisciplinarity

Resumen

Comunicamos la puesta en marcha de un programa intensivo y multidisciplinar de pérdida de peso en pacientes con obesidad mórbida (OM). Este ensayo clínico se basa en la educación para la salud, el apoyo en el proceso de cambio, los medicamentos y las sesiones de terapia de grupo. Nuestra intención es demostrar que los resultados obtenidos con este programa de pérdida de peso a 2 años son, cuando menos, comparables a los resultados que se obtienen con la cirugía bariátrica en estos pacientes con OM. Es nuestra intención igualmente demostrar que este tratamiento multidisciplinar induce una mejoría de las comorbilidades y está asociado a un menor gasto en el presupuesto de nuestro Sistema Nacional de Salud.

Palabras clave:

Programa de pérdida de peso

Educación para la salud

Metodología de investigación

Obesidad mórbida

Ensayo clínico

Interdisciplinariedad

Full text is only aviable in PDF

References

[1.]

B. Burguera, A. Agusti, P. Arner, A. Baltasar, F. Barbe, A. Barcelo, et al.

Critical assessment of the current guidelines for the management and treatment of morbidly obese patients International Symposium on Morbid Obesity. Morbid Obesity and its Comorbodities: an Interdisciplinary Approach.

J Endocrinol Invest, 30 (2007), pp. 844-852

Medline

[2.]

K.M. Flegal, M.D. Carroll, D.L. Ogden, C.L. Johnson.

Prevalence and trends in obesity among US adults, 1999–2000.

JAMA, 288 (2002), pp. 1723-1727

Medline

[3.]

J.A. Martinez, B. Moreno, M.A. Martinez-Gonzalez.

Prevalence of obesity in Spain.

Obes Rev, 3 (2004), pp. 171-172

[4.]

N.I.H. Conference:.

Gastrointestinal surgery for severe obesity, Consensus Development Conference Panel.

Ann Intern Med, 115 (1991), pp. 956-961

[5.]

T.A. Wadden, G.D. Foster.

Behavioral treatment of obesity.

Med Clin North Am, 84 (2000), pp. 441-461

Medline

[6.]

R.R. Wing, E. Blair, M. Marcus, L.H. Epstein, J. Harvey.

Year-long weight loss treatment for obese patients with type 2 diabetes: does including an intermittent very-low-calorie diet improve outcome?.

Am J Med, 97 (1994), pp. 354-362

Medline

[7.]

R.R. Wing, Look AHEAD Research Group.

Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.

Arch Intern Med, 170 (2010), pp. 1566-1575

[8.]

D. Hofsø, N. Nordstrand, L.K. Johnson, T.I. Karlsen, H. Hager, T. Jenssen, et al.

Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention.

Eur J Endocrinol, 163 (2010), pp. 735-745

http://dx.doi.org/10.1530/EJE-10-0514 | Medline

[9.]

M.A. Van Baak, E. van Mil, A.V. Astrup, N. Finer, L.F. Van Gaal, J. Hilsted, STORM Study Group, et al.

Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial).

Am J Clin Nutr, 78 (2003), pp. 209-214

Medline

[10.]

D.E. Arterburn, P.K. Crane, D.L. Veenstra.

The efficacy and safety of sibutramine for weight loss: a systematic review.

Arch Intern Med, 164 (2004), pp. 994-1003

http://dx.doi.org/10.1001/archinte.164.9.994 | Medline

[11.]

J.S. Torgerson, J. Hauptman, M.N. Boldrin, L. Sjöström.

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

Diabetes Care, 27 (2004), pp. 155-161

Medline

[12.]

E. Muls, J. Kolanowski, A. Scheen, L. Van Gaal, ObelHyx Study Group.

The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.

Int J Obes Relat Metab Disord, 25 (2001), pp. 1713-1721

http://dx.doi.org/10.1038/sj.ijo.0801814 | Medline

[13.]

A. Kaya, N. Aydin, P. Topsever, M. Filiz, A. Oztürk, A. Dağar, et al.

Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.

Biomed Pharmacother, 58 (2004), pp. 582-587

http://dx.doi.org/10.1016/j.biopha.2004.09.006 | Medline

[14.]

T.A. Wadden, R.I. Berkowitz, D.B. Sarwer, R. Prus-Wisniewski, C. Steinberg.

Randomized trial of lifestyle modification in the pharmacologic treatment of obesity.

N Engl J Med, 353 (2005), pp. 2111-2120

http://dx.doi.org/10.1056/NEJMoa050156 | Medline